Mediwound Ltd (MDWD) reported quarterly earnings results on Thursday, Jul-28-2016. The company reported $-0.34 earnings per share for the quarter, missing the analyst consensus estimate by $-0.11. Analysts had a consensus of $-0.23. The company posted revenue of $.36 million in the period, compared to analysts expectations of $.45 million. The company’s revenue was up 115.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.19 EPS.
Mediwound Ltd opened for trading at $7.68 and hit $7.82 on the upside on Thursday, eventually ending the session at $7.7, with a gain of 0.13% or 0.01 points. The heightened volatility saw the trading volume jump to 21,079 shares. Company has a market cap of $168 M.
MediWound Ltd. is a fully integrated biopharmaceutical company. The Company is focused on developing manufacturing and commercializing products to address unmet needs in the fields of severe burns chronic and other hard-to-heal wounds and connective tissue disorders. The Companys biopharmaceutical product NexoBrid which is based on its patented proteolytic enzyme technology represents a new paradigm in burn care management and its clinical trials have demonstrated with statistical significance its ability to non-surgically and rapidly remove the eschar earlier upon patient admission without harming viable tissues. The Company launched NexoBrid in December 2013 in the European Union through its wholly-owned German subsidiary targeting a focused audience of burn specialists treating patients in burn centers and hospital burn units.